Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
3.
Tumour Biol ; 37(5): 6769-73, 2016 May.
Article in English | MEDLINE | ID: mdl-26662304

ABSTRACT

In this study, we evaluate the clinical significance of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 (WAVE1) in patients with epithelial ovarian cancer (EOC) by immunohistochemistry.In current study, all adjacent non-cancerous tissues showed absent or low expression of PRSS3. The expression of PRSS3 was significantly increased in the EOCs than adjacent non-cancerous tissues. Moreover, the expression of WAVE1 was significantly observed in all EOC tissues when compared with normal tissues. Furthermore, WAVE1 expression was absent in 35 (89.74 %) adjacent non-cancerous tissues.Our findings showed that high expression of PRSS3 was markedly linked to FIGO stage (P = 0.02), advanced grade (P = 0.017), and lymph node metastases (P = 0.001), but no relationship was determined with other clinicopathological parameters. Furthermore, high expression of WAVE1 was significantly correlated with FIGO stage (P = 0.001), grade of tumor (P = 0.011), and residual tumor size (P = 0.041), but no significant associations were found between WAVE1 expression and age, lymph node metastasis, and histological subtypes (all P > 0.05). In conclusion, our study showed that increased expression of PRSS3 and WAVE1 may be involved in development of EOC.


Subject(s)
Biomarkers, Tumor , Neoplasms, Glandular and Epithelial/diagnosis , Neoplasms, Glandular and Epithelial/metabolism , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/metabolism , Trypsin/metabolism , Wiskott-Aldrich Syndrome Protein Family/metabolism , Adult , Aged , Carcinoma, Ovarian Epithelial , Early Detection of Cancer , Female , Gene Expression , Humans , Immunohistochemistry , Lymphatic Metastasis , Middle Aged , Neoplasm Grading , Neoplasm Metastasis , Neoplasm Staging , Prognosis , Trypsin/genetics , Wiskott-Aldrich Syndrome Protein Family/genetics
4.
Tumour Biol ; 37(6): 7583-7, 2016 Jun.
Article in English | MEDLINE | ID: mdl-26687644

ABSTRACT

In order to evaluate the correlation of B7-H4 and B7-H1 with renal cell carcinoma (RCC), we analyzed B7-H1 and B7-H4 expressions and their clinical significance by immunohistochemical method. Our result indicated that B7-H4-positive staining was detected in 58.13 % of RCC tissues (25 tissues tumors), and there were 18 tissues of patients without detectable B7-H4. Furthermore, 21 cases (48.83 %) were B7-H1-positive. Positive tumor expressions of B7-H4 and B7-H1 were markedly related to advanced TNM stage (P = 0.001; P = 0.014), high grade (P = 0.001; P = 002), and larger tumor size (P = 0.002; P = 024) in RCC tissues than patients with B7-H4-negative and B7-H1-negative in RCC tissues. The patients with B7-H1 and B7-H4-positive expressions were found to be markedly correlated with the overall survival of the patients (P < 0.05) and tended to have an increased risk of death when compared with negative expression groups. Univariate analysis showed that B7-H4 and B7-H1 expressions, TNM stage, high grade, and tumor size were significantly related to the prognosis of RCC. Furthermore, multivariate analysis showed that B7-H4 and B7-H1 expressions decreased overall survival. The adjusted HR for B7-H1 was 2.83 (95 % CI 1.210-2.971; P = 0.031) and also was 2.918 (95 % CI 1.243-3.102; P = 0.006) for B7-H4 that showed these markers were independent prognostic factors in RCC patients. The expressions of B7-H1 and B7-H4 in RCC patients indicate that these markers may be as a predictor of tumor development and death risk. Further investigations can be helpful to confirm B7-H1 and B7-H4 roles as an independent predictor of clinical RCC outcome.

SELECTION OF CITATIONS
SEARCH DETAIL
...